1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in Europe Countries, November 2019

Healthcare Analysis & Statistics in Europe Countries, November 2019

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Firstword Pharma

data types

1-19 of 19 reports

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

  • $ 6948
  • Industry report
  • March 2018

In the EU5, several of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team ...

  • Industries : Health Services
  • Countries : United Kingdom
Market Access Impact: Melanoma (EU5) 2018

Market Access Impact: Melanoma (EU5) 2018

  • $ 5865
  • Industry report
  • February 2018

Market barriers affect a fifth of melanoma prescriptions. Is your brand losing out?In the EU5, market barriers affect a fifth of all melanoma prescriptions, giving the top brand a narrow lead over two ...

  • Industries : Health Services
  • Countries : United Kingdom, United States
Targeted Therapies in Asthma: KOL Insight [2018]

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • Industry report
  • February 2018

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Industries : Therapy, Medical Biotechnology, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, North America, United Kingdom
Psoriasis: Update Bulletin [January 2018]

Psoriasis: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the Psoriasis market. Topics covered include: Initiation of thePhase III BE VIVID trial for UCB’s bimekizumab (CDP-4940); ...

  • Industries : Pathology, Biotechnology
  • Countries : Europe, European Union
Cystic Fibrosis: Update Bulletin #3

Cystic Fibrosis: Update Bulletin #3

  • $ 1151
  • Industry report
  • December 2017

This edition presents world leading key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; expert opinions on Vertex Pharmaceuticals’ regulatory ...

  • Industries : Therapy
  • Countries : United States, Europe, World, European Union
Value Added Services in Cardiometabolic Diseases -- Payer views

Value Added Services in Cardiometabolic Diseases -- Payer views

  • $ 2537
  • Industry report
  • October 2017

Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post ...

  • Industries : Chronic Disease
  • Countries : United States, World, European Union
Colorectal Cancer [2017]

Colorectal Cancer [2017]

  • $ 8658
  • Industry report
  • September 2017

Will new targeted therapies transform the treatment of colorectal cancer?Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal cancer. ...

  • Industries : Therapy, Cancer, Pathology
  • Countries : United States, United Kingdom
Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2017

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2017

  • $ 5637
  • Industry report
  • August 2017

Eliminating prescription barriers could break the tie at the top of the marketThe two leading brands in the EU5 non-small cell lung cancer (NSCLC) market are tied for market share, but one of them benefits ...

  • Industries : Health Services
  • Countries : United Kingdom
Market Access Impact: Multiple Sclerosis (EU5) 2017

Market Access Impact: Multiple Sclerosis (EU5) 2017

  • $ 5637
  • Industry report
  • July 2017

Market barriers affect nearly 15% of multiple sclerosis prescriptions in the EU5 In the EU5 countries, market barriers affect a modest 15% of multiple sclerosis prescriptions, but they’re giving market ...

  • Industries : Health Services
  • Countries : France, Germany, Italy, Spain, United Kingdom
Market Access Impact: Haemophilia B (EU5)

Market Access Impact: Haemophilia B (EU5)

  • $ 5637
  • Industry report
  • July 2017

Leading brands have room to growAt least 30% of the haematologists we surveyed don’t prescribe the 7 leading haemophilia B treatments we asked them about. But most are willing to consider them, so there’s ...

  • Industries : Health Services
  • Countries : Sweden
Medical Affairs Reputations: Melanoma (EU5) 2017

Medical Affairs Reputations: Melanoma (EU5) 2017

  • $ 6755
  • Industry report
  • July 2017

Find out what the leading team gets right, and what the trailing team gets wrongThe medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists ...

  • Industries : Health Services
  • Countries : United Kingdom
Market Access Impact (EU5) [Melanoma]

Market Access Impact (EU5) [Melanoma]

  • $ 5637
  • Industry report
  • February 2017

DescriptionTwo brands are neck and neck for 2nd place. Would eliminating barriers break the tie?In the EU5, market barriers affect nearly a quarter of all melanoma prescriptions, giving the top brand a ...

  • Industries : Health Services
  • Countries : United States, United Kingdom
Idiopathic Pulmonary Fibrosis (IPF): KOL Insight

Idiopathic Pulmonary Fibrosis (IPF): KOL Insight

  • $ 8379
  • Industry report
  • June 2016

What’s on the KOL ‘wish list’ for the next generation of IPF treatments?Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them? ...

  • Industries : Health Services, Therapy
  • Countries : United States, North America, Italy
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

  • $ 1077
  • Industry report
  • January 2016

Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : European Union, United States
Physician Views: Evaluating the launch of Novartis' Cosentyx for psoriasis

Physician Views: Evaluating the launch of Novartis' Cosentyx for psoriasis

  • $ 781
  • Industry report
  • June 2015

Approved in both the US and EU at the beginning of the year, Novartis' first-to-market IL-17 inhibitor Cosentyx could be the most effective psoriasis treatment available, suggest key opinion leaders recently ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, European Union
Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

  • $ 634
  • Industry report
  • June 2015

The question of whether to approve Regeneron and Sanofi’s Praluent (alirocumab) and Amgen’s Repatha (evolocumab) never really seemed to be in doubt at FDA’s Endocrinologic and Metabolic Drugs Advisory ...

  • Industries : Therapy
  • Countries : United States, European Union
Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)

Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)

  • $ 7638
  • Industry report
  • May 2015

Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists. Personalised Medicines ...

  • Industries : Health Services
  • Countries : France, Germany, Spain, Italy
Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

  • $ 781
  • Industry report
  • January 2015

Novartis has become the first player to bring to market an interleukin-17A inhibitor, most recently announcing on Monday that the European Commission approved Cosentyx for the treatment of moderate-to-severe ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, Europe, European Union
Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?

Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?

  • $ 781
  • Industry report
  • April 2014

According to analysts at Barclays, oncology continues to attract around one-third of pharma's total R&D investment. This trend is driven by a number of factors, not least the commercial opportunity afforded ...

  • Industries : Therapy
  • Countries : United Kingdom



Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on